Peptide Therapeutics Market Surges Past $130 Billion as Industry Enters Scale-Up Phase

A Market in Rapid Expansion

The global peptide therapeutics market has entered a period of sustained acceleration, reaching an estimated $131.95 billion in 2025 and projected to grow to $146.34 billion in 2026, according to data from Fortune Business Insights. The trajectory points toward $334.95 billion by 2034, representing a compound annual growth rate of 10.91% over the forecast period.

Multiple market research firms confirm the trend, though estimates vary in exact figures. Grand View Research projects the market reaching $294.58 billion by 2033 at an 8.73% CAGR, while Precedence Research forecasts $87.21 billion by 2035 using a narrower market definition. Regardless of methodology, the consensus is clear: peptide therapeutics represent one of the fastest-growing segments in pharmaceuticals.

Novo Nordisk and Eli Lilly Dominate

Two companies have established commanding positions in the peptide therapeutics space. Novo Nordisk reported $45.9 billion in 2025 revenue, driven largely by its GLP-1 receptor agonist franchise including Wegovy and Ozempic. Eli Lilly posted $65.2 billion in 2025 revenue, with its diabetes and obesity portfolio — anchored by tirzepatide (Mounjaro/Zepbound) — contributing significantly to growth.

Both companies are making substantial capital commitments to maintain their competitive positions. In December 2025, Eli Lilly announced plans to invest more than $6 billion in a new active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, focused on peptide and small-molecule production. The company also built over $1.5 billion in pre-launch inventory for orforglipron (Foundayo), its oral GLP-1 pill approved in 2026.

Novo Nordisk is expanding manufacturing capacity in Ireland to support international supply of oral Wegovy, while investing in telehealth partnerships through NovoCare Pharmacy to broaden patient access.

Strategic Partnerships Accelerate

The partnership landscape has intensified across the peptide sector. In February 2026, Zonsen PepLib Biotech entered a global collaboration with Eli Lilly to advance novel peptide-based drug candidates. In August 2025, BioMed X and Novo Nordisk partnered to develop novel oral-formulation technologies for therapeutic peptides.

AstraZeneca signaled its own commitment to the space in March 2026 with a $2.5 billion investment in a new R&D center, manufacturing facilities, and biotech collaborations in Beijing. On the startup side, Pepticom secured $6.6 million in January 2025 to scale its AI-powered peptide discovery platform.

In total, more than 75 partnership agreements have been signed among peptide therapeutics developers in recent years, with cumulative funding exceeding $7 billion. The majority of capital has arrived through secondary offerings, indicating that the industry has moved past the speculative phase into sustained scale-up investment.

GLP-1 Therapies Drive the Surge

The GLP-1 receptor agonist class has become the primary growth engine for the market. The approval of generic Saxenda (liraglutide injection) by Teva Pharmaceuticals in August 2025 — the first generic GLP-1 for weight loss — marked a significant pricing milestone that could expand market access to a broader patient population.

The oral GLP-1 segment is emerging as the next competitive frontier, with Novo Nordisk's oral Wegovy (approved December 2025) and Eli Lilly's Foundayo both targeting patients who prefer pills over injections. Analysts project that oral formulations could capture a substantial share of the obesity and diabetes treatment market as manufacturing scales and costs decline.

Beyond Obesity: Expanding Therapeutic Applications

While metabolic disorders drive the largest revenue share, peptide therapeutics are expanding into oncology, cardiovascular disease, rare diseases, and regenerative medicine. The increasing availability of compounded peptides such as BPC-157, TB-500, and others following the FDA's 2026 reclassification actions adds another dimension to market growth.

AI-driven drug discovery is further accelerating the pipeline. Companies are applying machine learning and enzyme engineering to design novel peptide sequences with improved stability, selectivity, and bioavailability — reducing development timelines and production costs.

Outlook

The peptide therapeutics market is positioned for continued expansion through the remainder of the decade. The combination of blockbuster GLP-1 revenues, expanded compounding access, oral delivery breakthroughs, and AI-accelerated discovery creates a favorable environment for both established pharmaceutical companies and emerging biotech firms. Investors and practitioners alike should expect the pace of innovation — and competition — to intensify.